Matt Brauer’s Post

✌️ A special shoutout to Jamie Justice, Ph.D., a Consortium Member, as well as her exceptional team at XPRIZE, for leading the charge in this monumental $101 million, 7-year global competition. 💊 The initiative, as highlighted in the Nature Aging Worldview article linked below, aims to catalyze the development of interventions dedicated to restoring function lost due to age-related decline in multiple organ systems in humans. Link to article: https://lnkd.in/eGyeWNi7 💫 We are thrilled to collaborate on synergistic initiatives, particularly our Biomarker Challenge Series, with its aim to identify and benchmark cutting-edge biomarkers that may have the potential to serve as reliable predictors of aging-related outcomes for interventions.

🌐 Exploring the Growth Trajectory of Small Animal Imaging (In-Vivo) Market 🐭 Embark on a journey of innovation and growth within the Small Animal Imaging (In-Vivo) market! From $2.59 billion in 2023 to a projected $4.55 billion by 2028, the market demonstrates an impressive CAGR of 11.8%. Key Growth Drivers: 🧬 Surge in Preclinical Research 🚀 Expansion in Pharmaceutical and Biotech Sectors 🌐 Integration of AI in Imaging Technologies Anticipated Trends: 🔍 Emergence of Novel Imaging Probes 🔄 Upsurge in Preclinical Contract Research Organizations (CROs) 🌈 Adoption of Advanced Multimodal Imaging Techniques Chronic Diseases Propel Expansion: 📈 Rise in Chronic Disease Incidence 🏥 Imaging's Vital Role in Chronic Disease Research Market Players & Segmentation: 🏢 Leading Companies: Bruker, PerkinElmer, Miltenyi Biotec, Siemens 🎯 Market Segments: Micro-MRI, Optical Imaging, Nuclear Imaging Technological Strides: 🌐 Introduction of PerkinElmer’s Vega Imaging System 🤝 Strategic Acquisition by Rigaku Corporation Regional Dynamics: 🌍 North America at the Forefront 🚀 Accelerated Growth Prospects in Europe Conclusion: Seize the opportunity in this vibrant landscape! With technological advancements and a focus on chronic diseases, the Small Animal Imaging (In-Vivo) market promises a dynamic future. #SmallAnimalImaging #InVivoImaging #HealthcareInnovation #ResearchTech #MedicalImaging #TheBusinessResearchCompany #LinkedInPost #MarketInsights #HealthcareResearch #AnimalResearch #GlobalMarketAnalysis

Today marks the end of the Asteroid era for me. It has a been a two year whirlwind of great science, wonderful people and excitement. I'm sad to see it go, but I am using this change as a catalyst to launch a new adventure in independent consulting. So if you or someone you know has DMPK, ADME or preclinical development questions, hit me up at Flatbush Consulting!

Check out the amazing work by Martijn Rijnberg and his team translating mechanisms of action into animation! These animations are a great tool to visually introduce your mechanism of action on your website, in social, or in your corporate presentation. Is this on your to do list for 2024? Let’s talk!

Kicking off 2024, we are thrilled to present our new film titled "Code of Life" which serves as an ode to genomics. This film incorporates segments from our Mode of Action animation projects, showcasing a diverse range of topics from circular RNAs to genomically recoded organisms. Each segment exemplifies a distinct visual style, tailored specifically to give every project its own unique look. Within this compilation, you will find several segments from our award-winning films. These films have been highly acclaimed at prestigious film festivals such as Global Awards, renowned for their exclusive focus on science and healthcare, as well as New York Festivals, often regarded as the commissioned film industry's equivalent to the Oscars. Thank you so much, Johnson & Johnson Innovative Medicine, GRO Biosciences, Laronde, Rejuvenation Technologies Inc. (recent illustrations), LaVoieHealthScience, Norvell Jefferson, Flagship Pioneering, Scient Public Relations, Donna L. LaVoie, Nicole Verbeeck, Peter Peeters, Bart Van Cauwenbergh, Kristi Bruno, Courtney Heath, Michael Lampe, Diego Miralles, Sophie de Boer, John Ramunas, Suzana Tulac, Dan Mandell, Lisa DeScenza, among others, for making these kind of projects possible. We wish you a wonderful year in 2024! On a separate note, we are very happy to share that our YouTube channel, https://lnkd.in/g94ziSB8, has reached a milestone of 96k subscribers in 2023. Please feel free to contact us with any questions regarding animation or illustration. We would love to help translate your science! [email protected]. Cortical Studios Glow Studio - Animation Illuminates Science #genetherapy #circular #genomics #dna #genomics #circularrna #rna #messengerrna #gene #biotech #pharmaceutical #geneediting #crispr #crispr-cas #erna #modeofaction #genetics #translation #proteinsynthesis #ribosome #transcription #moaanimation #mechanismofaction #biotech #ribosomes #3danimation #pharmaceutical #lifesciences #glowmedical #corticalstudios #animationilluminatesscience 

Ashley Magargee's ascendancy to Genentech CEO says as much about the company's past as its future. Genentech Nupur Mankar Srinivas Jakka Diya Das, PhD Ebenezer Byard Gandi Kinjal Zaveri Hatibe Kabulantok Evelyn A Camille Dycke Catherine Ross Sally Madden Wojciech Fl #pentoz #january #january2024 #Technology #tech #ai #innovation #innovation2024 #innovation #news #newsupdate #update #ceo

Excited to announce that FaunaBio and Eli Lilly and Company have announced a strategic collaboration to discover novel #obesity targets using its #Convergence AI platform in a deal worth up to $494M. 🚀🚀🚀 Fauna's Convergence™ AI platform analyzes data collected from the protective adaptations of hibernation biology (and other extreme adaptations) to identify drug targets for humans. Fauna identifies the best genes to target for efficacy in diseases with high unmet need and can identify genes to target within a broad range of treatment modalities. "We are very excited to enter into this collaboration with Lilly, which showcases the power of our Convergence™ AI platform to rapidly identify novel targets for complex disease areas of high unmet need," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio. "Lilly is a leader in obesity treatment, and our approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development." Read the full release: 👇👇👇 https://lnkd.in/eXKDEKze

Ever consider how Medicines Discovery Catapult could support you? Our team will work with you to develop and deliver your project strategy, providing industrial medicines discovery expertise and undertaking cutting-edge laboratory work and Virtual R&D services as required. We will help advance your idea from the initial concept to the clinic by unblocking your project at places where you do not have the internal technology or expertise. Throughout the process, we will ensure that the right experiments are carried out, and the right data is captured, helping you safeguard the future of your intellectual property. #drugdiscovery #biomarker #imaging #massspectrometry #spatialbiology #proteomics #spatialtranscriptomics #informatics #cellbiology

FogPharma CEO Mathai Mammen, M.D., Ph.D., will be at the rEVOLUTION Symposium this week in Washington, DC, to moderate a panel on the inevitability and utility of AI in the development of therapies for patients. The rEVOLUTION meeting is held every 1-2 years in DC, and brings together thought leaders to tackle some of R&D’s most significant challenges. The location also allows significant participation by DC’s policymakers and regulators.   Joining Mathai for this important discussion will be Nicolle Gatto, Ph.D., Chief Scientific Officer at Aetion; Najat Khan, PhD, Former Chief Data Science Officer & Global Head, Strategy & Portfolio, R&D at Johnson & Johnson; Eric Schadt, Ph.D., Chief Scientific Officer at Pathos; and other leaders.    AI, and data science broadly, are technologies we’re passionate about at FogPharma. Today, a lot of attention is being paid to the role of data science in drug discovery, but in fact some of the biggest gains in the near term will be made in drug development. Numerous resource-intensive, strategically critical drug development challenges — including clinical site selection, patient recruitment, protocol design, endpoint definition, responder and non-responder signatures, and synthetic control arms — will be revolutionized by data science in the coming years.   At Fog, we hope to combine experimental science and these sorts of data science advances to revolutionize the discovery and development of transformational medicines.    Explore the rEVOLUTION event agenda here:  https://bit.ly/44jUIoH   #drugdiscovery #artificialIntelligence #datascience #oncology